Skip to main content
Contact Us
Sign Up
Subscriber Sign In
Switch language
English
Japanese
navigation
サイト内検索
COVID-19
COVID-19 Update
COVID-19 EventAnalyzer
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
EvaluatePharma Vision
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
University College London
August 28, 2017
ESC 2017 – The corpse of renal denervation starts twitching
June 22, 2016
First human Crispr trial is a go, but don’t ask about the IP
April 14, 2016
Interview – UK cell therapy minnow squares up to Juno
April 13, 2016
First-quarter venture financing: the retrenchment begins
February 04, 2016
Imperial marches against the tide with big funding round
December 15, 2015
Interview – Leucid Bio swings for the fences in CAR-T
December 08, 2015
ASH – CAR-T struggles to travel beyond leukaemia
November 19, 2015
A bittersweet outcome for Cellectis
November 06, 2015
ASH preview – Cellectis steals the limelight
June 29, 2015
Big pharma picks Immunocore as a cell therapy player to watch
June 16, 2015
Licence marks Atara as a new cell therapy contender
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
April 16, 2020
Evaluate Vantage COVID-19 Report
February 20, 2020
Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review
Editor's Picks
April 22, 2020
Covid-19 antibody tests face a very specific problem
June 17, 2020
Big pharma sports smallest late-stage pipeline for a decade
June 05, 2020
How best to develop a liquid biopsy?
June 18, 2020
All still for play for in haemophilia gene therapy race
May 20, 2020
J&J holds its own on sales per employee
